{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:48:15Z","timestamp":1784166495059,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Extended-release naltrexone\/bupropion (NB) is indicated for chronic weight management. Incretin agents are recommended for patients with type 2 diabetes. This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a post-hoc analysis of NB vs. placebo (PL) among subjects with type 2 diabetes stable on an incretin agent prior to randomization in a double-blind, PL-controlled cardiovascular outcome trial (<jats:italic>N<\/jats:italic>\u2009=\u20091317).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Over 1 year, mean weight loss was significantly greater among NB patients vs. PL among those taking DPP-4i (mean absolute difference 4.6% [<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001]) and those taking GLP-1RAs (mean absolute difference 5.2%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Proportions of subjects achieving 5% weight loss were significantly greater for NB vs. PL at weeks 26 and 52 among those taking DPP-4is or GLP-1RAs. There were no significant differences in effectiveness observed between NB\u2009+\u2009DPP-4i and NB\u2009+\u2009GLP-1RA or between PL\u2009+\u2009DPP-4i and PL\u2009+\u2009GLP-1RA in any of the analyses. Serious adverse events were reported by 9.1% and 11.1% for PL\u2009+\u2009DPP-4i and PL\u2009+\u2009GLP-1RA, respectively, and 13.3% and 12.4% of NB\u2009+\u2009DPP-4i and NB\u2009+\u2009GLP-1RA, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>NB appears to be effective in reducing weight in patients with T2DM and obesity\/overweight who are taking DPP-4ihibitors or GLP-1RA. The SAE rates in all arms of this analysis were lower than have been reported in other cardiovascular outcome trials in type 2 diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41366-021-00831-4","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T17:02:56Z","timestamp":1622739776000},"page":"1687-1695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Extended-release naltrexone\/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0111-1530","authenticated-orcid":false,"given":"Sean","family":"Wharton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melonie","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3883-0563","authenticated-orcid":false,"given":"Errol","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Blavignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5212-8688","authenticated-orcid":false,"given":"Rebecca A. G.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"831_CR1","first-page":"252","volume-title":"Evidence-based diabetes care. Hamilton","author":"RR Wing","year":"2000","unstructured":"Wing RR. Weight loss in the management of type 2 diabetes. In: Gerstein HC, Hyanes B, eds. Evidence-based diabetes care. Hamilton. B.C. Decker Inc.; 2000. p. 252\u201376."},{"issue":"Suppl 1","key":"831_CR2","first-page":"S124","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee, Wharton S, Pedersen SD, Lau DCW, Sharma AM.","year":"2018","unstructured":"Diabetes Canada Clinical Practice Guidelines Expert Committee, Wharton S, Pedersen SD, Lau DCW, Sharma AM. Weight management in diabetes. Can J Diabetes. 2018;42(Suppl 1):S124\u20139.","journal-title":"Can J Diabetes."},{"key":"831_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595\u2013605.","journal-title":"Lancet."},{"key":"831_CR4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935\u201343.","journal-title":"Obesity."},{"key":"831_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O\u2019Neil PM, et al. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110\u201320.","journal-title":"Obesity."},{"key":"831_CR6","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022\u20139.","journal-title":"Diabetes Care"},{"key":"831_CR7","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1210\/jc.2012-2396","volume":"97","author":"A Vella","year":"2012","unstructured":"Vella A. Mechanism of action of DPP-4 inhibitors\u2014new insights. J Clin Endocrinol Metab. 2012;97:2626\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"831_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2215\/CJN.06080616","volume":"12","author":"EJ van Bommel","year":"2017","unstructured":"van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017;12:700\u201310.","journal-title":"Clin J Am Soc Nephrol"},{"key":"831_CR9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315:990\u20131004.","journal-title":"JAMA."},{"issue":"Suppl 1","key":"831_CR10","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","volume":"43","author":"American Diabetes Association.","year":"2020","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98\u2013S110.","journal-title":"Diabetes Care."},{"key":"831_CR11","doi-asserted-by":"crossref","unstructured":"Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;43:487\u201393.","DOI":"10.2337\/dci19-0066"},{"key":"831_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jcjd.2020.08.001","volume":"44","author":"L Lipscombe","year":"2020","unstructured":"Diabetes Canada Clinical Practice Guidelines Expert Committee, Lipscombe L, Butalia S, Dasgupta K, Eurich DT, MacCallum L, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes. 2020;44:575\u201391.","journal-title":"Can J Diabetes."},{"key":"831_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"831_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"831_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0170-y","volume":"16","author":"S Hollis","year":"2016","unstructured":"Hollis S, Fletcher C, Lynn F, Urban HJ, Branson J, Burger HU, et al. Best practice for analysis of shared clinical trial data. BMC Med Res Methodol. 2016;16:76.","journal-title":"BMC Med Res Methodol"},{"key":"831_CR16","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE\u00ae (empagliflozin) prescribing information (revised). 2020."}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41366-021-00831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41366-021-00831-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41366-021-00831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:19:01Z","timestamp":1684617541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-021-00831-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["831"],"URL":"https:\/\/doi.org\/10.1038\/s41366-021-00831-4","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"18 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SW is the owner and director of Wharton Medical Clinic (WMC). He has previously received funding in the form of grants for research from the Canadian Institutes of Health Research and Mitacs. He has also received funding from Novo Nordisk, Bausch Health Canada Inc., Eli Lilly and Company, Janssen Pharmaceuticals, and AstraZeneca for advisory work. EK and RAGC are currently employed by the Wharton Medical Clinic. PY is an employee of Bausch Health Companies. MB (Melonie Burrows) is a former employee of Bausch Health Companies. JB and MB (Maxime Barakat) are employees of, and shareholders in, Bausch Health Companies. FC received consulting fees from Bausch Health, Abbvie Corporation, and Janssen Inc. EG is an employee of Currax Pharmaceuticals LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}